Two Bifidobacterium strains have been added to its portfolio which is currently dominated by Lactobacillus strains.
The two Bifidobacterium strains are Bifidobacterium bifidum PRO G814 and Bifidobacterium animalis subsp. lactis PRO G952.
CJ Bio debuted these two strains under its ingredients brand trademarked BiomeNrich during last week’s Vitafoods Europe held at Barcelona. This is also the first time that the company has participated in the tradeshow.
BiomeNrich consists of both pro- and postbiotics ingredients.
Including the two strains, the BiomeNrich brand currently has nine probiotic ingredient strains in total.
Speaking to NutraIngredients-Asia at the trade show, Soohyun Paik, business development manager, said that the move would put the brand in a better stead in developing new and innovative products for its partners.
“As our current probiotic portfolio mostly consists of Lactobacillus strains, we decided to expand it by adding scientifically proven Bifidobacterium strains.
“This move creates more opportunities for Consumer Packaged Goods (CPG) and Contract Development and Manufacturing Organization (CDMO) companies in the nutrition market to develop new and innovative products,” she explained.
An example of its Lactobacillus ingredient strain is Lactobacillus plantarum PRO E133 for strengthening skin immunity.
Its portfolio also includes strains such as Limosilactobacillus fermentum PRO W002 for weight loss and pastuerised Akkermansia muciniphila POSR M005 for supporting muscle health.
The two newly added Bifidobacterium strains focus on supporting gut microbiome balance.
Bifidobacterium bifidum PRO G814 is also a Human-Residential Bifidobacteria (HRB) isolated from the faeces of healthy breastfed infants.
“It is known for its ability to increase folate biosynthesis, utilise Human Milk Oligosaccharides (HMOs) and strongly adhering to the gut lining.
“Scientific studies have shown its benefits in improving defecation discomfort, stool frequency, abdominal pain, skin immunity, and even cognitive function,” she said.
Also isolated from healthy breastfed infants, Bifidobacterium animalis subsp. lactis PRO G952 is said to have strong survivability and adhesion capacity to intestinal epithelial cells.
“Scientific evidence supports its effectiveness in alleviating defecation discomfort, irregular stool frequency, and abdominal pain,” she said.
In fact, research on these two strains can be dated back to 30 years ago. Its clinical findings have been published on journals such as Clinical Nutrition in 2023 and Pediatric Allergy and Immunology in 2010.
“BiomeNrich PRO G814 and PRO G952 have been studied over the course of 30 years of scientific research, demonstrating the positive effects of these strains on gut health.
“They are supported by a total of 11 clinical studies, multiple certifications such as Kosher and Halal, and confirmed safety — including GRAS status, a completed New Dietary Ingredient Notifications (NDIN) filing, and inclusion on the Qualified Presumption of Safety (QPS) list," she said.
With the certifications, she said this would not only help boost manufacturers and consumer confidence, it would also allow for broader application of these live probiotic ingredients in both food and supplements.
She said that the markets of priorities would include the US, Europe, as well as Asia-Pacific.
“The target audience includes companies developing highly effective functional foods or supplements for gut health, particularly those seeking branded ingredients with strong scientific data.
“These strains are ideal for brands looking to incorporate innovative and clinically supported ingredients into their product lines to meet the growing consumer demand for digestive and overall wellness,” she said.
In the domestic South Korean market, CJ Group is also known for its probiotic consumer brand BYO, which is launched by its other subsidiary CJ Wellness.
